Edaravone in the Treatment of Optic Neuritis

First Affiliated Hospital of Guangxi Medical University50 enrolled

Overview

Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Optic Neuritis

Interventions

EdaravoneDRUG

Edaravone injection 30mg three times a day

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis 2. Patients with a first episode of optic neuritis in either eye 3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone Exclusion Criteria: 1. Myopia over 6 diopters 2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity

Locations (1)

Yi Du

Nanning, China

RECRUITING

Outcomes

Primary Outcomes

Best-corrected visual acuity

Best-corrected visual acuity will be measured by "Illiterate E"chart.

Time frame: 18 months

Secondary Outcomes

Ganglion cell-inner plexiform layer

Ganglion cell-inner plexiform layer will be measured by optical coherence tomography.

Time frame: 18 months

Peripapillary retinal nerve fiber layer

Peripapillary retinal nerve fiber layer will be measured by optical coherence tomography.

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.